Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer

Fabrice Denis; Ethan Basch; Anne Lise Septans; Jaafar Bennouna; Thierry Urban; Amylou C. Dueck; Christophe Letellier

doi:10.1001/jama.2018.18085

Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer

Fabrice Denis, Ethan Basch, Anne Lise Septans, Jaafar Bennouna, Thierry Urban, Amylou C. Dueck, Christophe Letellier

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	306-307
Number of pages	2
Journal	JAMA - Journal of the American Medical Association
Volume	321
Issue number	3
DOIs	https://doi.org/10.1001/jama.2018.18085
State	Published - Jan 22 2019

ASJC Scopus subject areas

General Medicine

Access to Document

10.1001/jama.2018.18085

Cite this

@article{45c943363f3148809f914f6e31285cfa,

title = "Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer",

author = "Fabrice Denis and Ethan Basch and Septans, {Anne Lise} and Jaafar Bennouna and Thierry Urban and Dueck, {Amylou C.} and Christophe Letellier",

note = "Funding Information: Conflict of Interest Disclosures: Dr Denis reported receiving personal fees from AstraZeneca, Ipsen, SIVAN Innovation, Pfizer, Chugai, and Roche. Dr Basch reported receiving research funding from the National Cancer Institute and Patient-Centered Outcomes Research Institute and personal fees (ie, payment for serving on the scientific advisory board) from the Centers for Medicare & Medicaid Services, SIVAN Innovation, and Noona. Dr Bennouna reported receiving personal fees from Lilly and Merck Sharp & Dohme. Dr Urban reported receiving personal fees from AstraZeneca and Novartis. No other disclosures were reported. Funding Information: Funding/Support: This study was supported by SIVAN Innovation.",

year = "2019",

month = jan,

day = "22",

doi = "10.1001/jama.2018.18085",

language = "English (US)",

volume = "321",

pages = "306--307",

journal = "JAMA - Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "3",

}

TY - JOUR

T1 - Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer

AU - Denis, Fabrice

AU - Basch, Ethan

AU - Septans, Anne Lise

AU - Bennouna, Jaafar

AU - Urban, Thierry

AU - Dueck, Amylou C.

AU - Letellier, Christophe

N1 - Funding Information: Conflict of Interest Disclosures: Dr Denis reported receiving personal fees from AstraZeneca, Ipsen, SIVAN Innovation, Pfizer, Chugai, and Roche. Dr Basch reported receiving research funding from the National Cancer Institute and Patient-Centered Outcomes Research Institute and personal fees (ie, payment for serving on the scientific advisory board) from the Centers for Medicare & Medicaid Services, SIVAN Innovation, and Noona. Dr Bennouna reported receiving personal fees from Lilly and Merck Sharp & Dohme. Dr Urban reported receiving personal fees from AstraZeneca and Novartis. No other disclosures were reported. Funding Information: Funding/Support: This study was supported by SIVAN Innovation.

PY - 2019/1/22

Y1 - 2019/1/22

UR - http://www.scopus.com/inward/record.url?scp=85060233746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060233746&partnerID=8YFLogxK

U2 - 10.1001/jama.2018.18085

DO - 10.1001/jama.2018.18085

M3 - Letter

C2 - 30667494

AN - SCOPUS:85060233746

SN - 0098-7484

VL - 321

SP - 306

EP - 307

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

IS - 3

ER -

Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this